Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

NCT07682896 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Graves' Disease

Interventions

DRUG: Experimental: YB-101
DRUG: Placebo YB-101

Sponsor

Yarrow Bioscience, Inc.